nodes	percent_of_prediction	percent_of_DWPC	metapath
Pramipexole—HTR2A—arteriole—atherosclerosis	0.00882	0.152	CbGeAlD
Pramipexole—HTR2A—vein—atherosclerosis	0.00526	0.0904	CbGeAlD
Pramipexole—HTR1B—artery—atherosclerosis	0.00445	0.0766	CbGeAlD
Pramipexole—HTR1D—artery—atherosclerosis	0.00431	0.0741	CbGeAlD
Pramipexole—HTR2A—hindlimb—atherosclerosis	0.00349	0.0601	CbGeAlD
Pramipexole—HTR1B—blood vessel—atherosclerosis	0.00347	0.0596	CbGeAlD
Pramipexole—HTR1D—blood vessel—atherosclerosis	0.00336	0.0577	CbGeAlD
Pramipexole—HTR2A—appendage—atherosclerosis	0.003	0.0515	CbGeAlD
Pramipexole—HTR2A—artery—atherosclerosis	0.00214	0.0368	CbGeAlD
Pramipexole—HTR2A—endothelium—atherosclerosis	0.00181	0.0311	CbGeAlD
Pramipexole—HTR1D—connective tissue—atherosclerosis	0.00172	0.0296	CbGeAlD
Pramipexole—HTR2A—blood vessel—atherosclerosis	0.00167	0.0287	CbGeAlD
Pramipexole—HTR1B—cardiovascular system—atherosclerosis	0.00155	0.0266	CbGeAlD
Pramipexole—HTR1D—cardiovascular system—atherosclerosis	0.0015	0.0258	CbGeAlD
Pramipexole—HTR2B—cardiovascular system—atherosclerosis	0.00139	0.024	CbGeAlD
Pramipexole—SLC22A1—adipose tissue—atherosclerosis	0.00133	0.0229	CbGeAlD
Pramipexole—HTR1A—cardiovascular system—atherosclerosis	0.00125	0.0215	CbGeAlD
Pramipexole—HTR2B—adipose tissue—atherosclerosis	0.00123	0.0211	CbGeAlD
Pramipexole—ADRA2A—connective tissue—atherosclerosis	0.00101	0.0173	CbGeAlD
Pramipexole—ADRA2C—adipose tissue—atherosclerosis	0.000967	0.0166	CbGeAlD
Pramipexole—SLC22A1—liver—atherosclerosis	0.000935	0.0161	CbGeAlD
Pramipexole—HTR2A—connective tissue—atherosclerosis	0.000856	0.0147	CbGeAlD
Pramipexole—ADRA2A—adipose tissue—atherosclerosis	0.000772	0.0133	CbGeAlD
Pramipexole—HTR2A—cardiovascular system—atherosclerosis	0.000744	0.0128	CbGeAlD
Pramipexole—ADRA2C—liver—atherosclerosis	0.000678	0.0117	CbGeAlD
Pramipexole—Eye disorder—Niacin—atherosclerosis	0.000674	0.0011	CcSEcCtD
Pramipexole—Flatulence—Simvastatin—atherosclerosis	0.000674	0.0011	CcSEcCtD
Pramipexole—Tinnitus—Niacin—atherosclerosis	0.000672	0.0011	CcSEcCtD
Pramipexole—Dysgeusia—Simvastatin—atherosclerosis	0.000669	0.0011	CcSEcCtD
Pramipexole—Flushing—Niacin—atherosclerosis	0.000669	0.0011	CcSEcCtD
Pramipexole—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000665	0.00109	CcSEcCtD
Pramipexole—Anaemia—Ezetimibe—atherosclerosis	0.000662	0.00109	CcSEcCtD
Pramipexole—Tinnitus—Pravastatin—atherosclerosis	0.000662	0.00108	CcSEcCtD
Pramipexole—Malaise—Lovastatin—atherosclerosis	0.000659	0.00108	CcSEcCtD
Pramipexole—Flushing—Pravastatin—atherosclerosis	0.000659	0.00108	CcSEcCtD
Pramipexole—Cardiac disorder—Pravastatin—atherosclerosis	0.000659	0.00108	CcSEcCtD
Pramipexole—Muscle spasms—Simvastatin—atherosclerosis	0.000657	0.00108	CcSEcCtD
Pramipexole—Vertigo—Lovastatin—atherosclerosis	0.000657	0.00108	CcSEcCtD
Pramipexole—Angiopathy—Niacin—atherosclerosis	0.000654	0.00107	CcSEcCtD
Pramipexole—Leukopenia—Lovastatin—atherosclerosis	0.000654	0.00107	CcSEcCtD
Pramipexole—Chills—Niacin—atherosclerosis	0.000647	0.00106	CcSEcCtD
Pramipexole—Malaise—Ezetimibe—atherosclerosis	0.000646	0.00106	CcSEcCtD
Pramipexole—Vision blurred—Simvastatin—atherosclerosis	0.000644	0.00106	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000641	0.00105	CcSEcCtD
Pramipexole—Tremor—Simvastatin—atherosclerosis	0.00064	0.00105	CcSEcCtD
Pramipexole—Alopecia—Niacin—atherosclerosis	0.000637	0.00104	CcSEcCtD
Pramipexole—Chills—Pravastatin—atherosclerosis	0.000637	0.00104	CcSEcCtD
Pramipexole—Insomnia—Rosuvastatin—atherosclerosis	0.000636	0.00104	CcSEcCtD
Pramipexole—Ill-defined disorder—Simvastatin—atherosclerosis	0.000634	0.00104	CcSEcCtD
Pramipexole—Palpitations—Ezetimibe—atherosclerosis	0.000633	0.00104	CcSEcCtD
Pramipexole—Paraesthesia—Rosuvastatin—atherosclerosis	0.000632	0.00104	CcSEcCtD
Pramipexole—Anaemia—Simvastatin—atherosclerosis	0.000632	0.00104	CcSEcCtD
Pramipexole—Malnutrition—Niacin—atherosclerosis	0.000628	0.00103	CcSEcCtD
Pramipexole—Erythema—Niacin—atherosclerosis	0.000628	0.00103	CcSEcCtD
Pramipexole—Alopecia—Pravastatin—atherosclerosis	0.000627	0.00103	CcSEcCtD
Pramipexole—Cough—Ezetimibe—atherosclerosis	0.000625	0.00102	CcSEcCtD
Pramipexole—Myalgia—Lovastatin—atherosclerosis	0.000622	0.00102	CcSEcCtD
Pramipexole—Chest pain—Lovastatin—atherosclerosis	0.000622	0.00102	CcSEcCtD
Pramipexole—Arthralgia—Lovastatin—atherosclerosis	0.000622	0.00102	CcSEcCtD
Pramipexole—Anxiety—Lovastatin—atherosclerosis	0.00062	0.00102	CcSEcCtD
Pramipexole—Dyspepsia—Rosuvastatin—atherosclerosis	0.000619	0.00102	CcSEcCtD
Pramipexole—Hypertension—Ezetimibe—atherosclerosis	0.000619	0.00101	CcSEcCtD
Pramipexole—Flatulence—Niacin—atherosclerosis	0.000618	0.00101	CcSEcCtD
Pramipexole—Malaise—Simvastatin—atherosclerosis	0.000616	0.00101	CcSEcCtD
Pramipexole—Tension—Niacin—atherosclerosis	0.000616	0.00101	CcSEcCtD
Pramipexole—Discomfort—Lovastatin—atherosclerosis	0.000615	0.00101	CcSEcCtD
Pramipexole—Vertigo—Simvastatin—atherosclerosis	0.000614	0.00101	CcSEcCtD
Pramipexole—Leukopenia—Simvastatin—atherosclerosis	0.000612	0.001	CcSEcCtD
Pramipexole—Chest pain—Ezetimibe—atherosclerosis	0.00061	0.001	CcSEcCtD
Pramipexole—Arthralgia—Ezetimibe—atherosclerosis	0.00061	0.001	CcSEcCtD
Pramipexole—Myalgia—Ezetimibe—atherosclerosis	0.00061	0.001	CcSEcCtD
Pramipexole—Nervousness—Niacin—atherosclerosis	0.00061	0.000999	CcSEcCtD
Pramipexole—Flatulence—Pravastatin—atherosclerosis	0.000609	0.000998	CcSEcCtD
Pramipexole—Dry mouth—Lovastatin—atherosclerosis	0.000608	0.000997	CcSEcCtD
Pramipexole—Tension—Pravastatin—atherosclerosis	0.000606	0.000994	CcSEcCtD
Pramipexole—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000606	0.000993	CcSEcCtD
Pramipexole—Dysgeusia—Pravastatin—atherosclerosis	0.000605	0.000992	CcSEcCtD
Pramipexole—Muscle spasms—Niacin—atherosclerosis	0.000603	0.000989	CcSEcCtD
Pramipexole—Discomfort—Ezetimibe—atherosclerosis	0.000603	0.000988	CcSEcCtD
Pramipexole—Pain—Rosuvastatin—atherosclerosis	0.000602	0.000986	CcSEcCtD
Pramipexole—Constipation—Rosuvastatin—atherosclerosis	0.000602	0.000986	CcSEcCtD
Pramipexole—Confusional state—Lovastatin—atherosclerosis	0.000601	0.000985	CcSEcCtD
Pramipexole—Nervousness—Pravastatin—atherosclerosis	0.0006	0.000983	CcSEcCtD
Pramipexole—Dry mouth—Ezetimibe—atherosclerosis	0.000597	0.000978	CcSEcCtD
Pramipexole—Muscle spasms—Pravastatin—atherosclerosis	0.000594	0.000973	CcSEcCtD
Pramipexole—Infection—Lovastatin—atherosclerosis	0.000592	0.000971	CcSEcCtD
Pramipexole—Vision blurred—Niacin—atherosclerosis	0.000591	0.000969	CcSEcCtD
Pramipexole—Confusional state—Ezetimibe—atherosclerosis	0.00059	0.000966	CcSEcCtD
Pramipexole—Thrombocytopenia—Lovastatin—atherosclerosis	0.000584	0.000957	CcSEcCtD
Pramipexole—Vision blurred—Pravastatin—atherosclerosis	0.000582	0.000954	CcSEcCtD
Pramipexole—Arthralgia—Simvastatin—atherosclerosis	0.000582	0.000953	CcSEcCtD
Pramipexole—Chest pain—Simvastatin—atherosclerosis	0.000582	0.000953	CcSEcCtD
Pramipexole—Myalgia—Simvastatin—atherosclerosis	0.000582	0.000953	CcSEcCtD
Pramipexole—Infection—Ezetimibe—atherosclerosis	0.000581	0.000952	CcSEcCtD
Pramipexole—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00058	0.00095	CcSEcCtD
Pramipexole—Anxiety—Simvastatin—atherosclerosis	0.00058	0.00095	CcSEcCtD
Pramipexole—Tremor—Pravastatin—atherosclerosis	0.000579	0.000949	CcSEcCtD
Pramipexole—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000575	0.000943	CcSEcCtD
Pramipexole—Discomfort—Simvastatin—atherosclerosis	0.000575	0.000942	CcSEcCtD
Pramipexole—Nervous system disorder—Ezetimibe—atherosclerosis	0.000574	0.00094	CcSEcCtD
Pramipexole—Ill-defined disorder—Pravastatin—atherosclerosis	0.000573	0.000939	CcSEcCtD
Pramipexole—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000573	0.000938	CcSEcCtD
Pramipexole—Anaemia—Pravastatin—atherosclerosis	0.000571	0.000936	CcSEcCtD
Pramipexole—Anorexia—Lovastatin—atherosclerosis	0.000568	0.000931	CcSEcCtD
Pramipexole—Skin disorder—Ezetimibe—atherosclerosis	0.000568	0.000931	CcSEcCtD
Pramipexole—Vertigo—Niacin—atherosclerosis	0.000564	0.000924	CcSEcCtD
Pramipexole—Syncope—Niacin—atherosclerosis	0.000563	0.000922	CcSEcCtD
Pramipexole—Confusional state—Simvastatin—atherosclerosis	0.000562	0.000922	CcSEcCtD
Pramipexole—Leukopenia—Niacin—atherosclerosis	0.000562	0.000921	CcSEcCtD
Pramipexole—Urticaria—Rosuvastatin—atherosclerosis	0.000559	0.000916	CcSEcCtD
Pramipexole—Oedema—Simvastatin—atherosclerosis	0.000558	0.000914	CcSEcCtD
Pramipexole—Malaise—Pravastatin—atherosclerosis	0.000557	0.000913	CcSEcCtD
Pramipexole—Abdominal pain—Rosuvastatin—atherosclerosis	0.000556	0.000912	CcSEcCtD
Pramipexole—Vertigo—Pravastatin—atherosclerosis	0.000555	0.00091	CcSEcCtD
Pramipexole—Palpitations—Niacin—atherosclerosis	0.000555	0.000909	CcSEcCtD
Pramipexole—Infection—Simvastatin—atherosclerosis	0.000554	0.000908	CcSEcCtD
Pramipexole—Leukopenia—Pravastatin—atherosclerosis	0.000553	0.000906	CcSEcCtD
Pramipexole—Loss of consciousness—Niacin—atherosclerosis	0.000552	0.000904	CcSEcCtD
Pramipexole—Cough—Niacin—atherosclerosis	0.000548	0.000897	CcSEcCtD
Pramipexole—Thrombocytopenia—Simvastatin—atherosclerosis	0.000546	0.000895	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000543	0.00089	CcSEcCtD
Pramipexole—Insomnia—Lovastatin—atherosclerosis	0.000539	0.000884	CcSEcCtD
Pramipexole—Cough—Pravastatin—atherosclerosis	0.000539	0.000884	CcSEcCtD
Pramipexole—Paraesthesia—Lovastatin—atherosclerosis	0.000536	0.000877	CcSEcCtD
Pramipexole—Arthralgia—Niacin—atherosclerosis	0.000534	0.000875	CcSEcCtD
Pramipexole—Myalgia—Niacin—atherosclerosis	0.000534	0.000875	CcSEcCtD
Pramipexole—Hypertension—Pravastatin—atherosclerosis	0.000534	0.000874	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000533	0.000873	CcSEcCtD
Pramipexole—Anorexia—Simvastatin—atherosclerosis	0.000532	0.000871	CcSEcCtD
Pramipexole—Dyspnoea—Lovastatin—atherosclerosis	0.000532	0.000871	CcSEcCtD
Pramipexole—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000531	0.000869	CcSEcCtD
Pramipexole—Insomnia—Ezetimibe—atherosclerosis	0.000529	0.000867	CcSEcCtD
Pramipexole—Arthralgia—Pravastatin—atherosclerosis	0.000526	0.000862	CcSEcCtD
Pramipexole—Chest pain—Pravastatin—atherosclerosis	0.000526	0.000862	CcSEcCtD
Pramipexole—Myalgia—Pravastatin—atherosclerosis	0.000526	0.000862	CcSEcCtD
Pramipexole—Paraesthesia—Ezetimibe—atherosclerosis	0.000525	0.000861	CcSEcCtD
Pramipexole—Dyspepsia—Lovastatin—atherosclerosis	0.000525	0.00086	CcSEcCtD
Pramipexole—Anxiety—Pravastatin—atherosclerosis	0.000524	0.000859	CcSEcCtD
Pramipexole—Dry mouth—Niacin—atherosclerosis	0.000523	0.000856	CcSEcCtD
Pramipexole—Dyspnoea—Ezetimibe—atherosclerosis	0.000522	0.000855	CcSEcCtD
Pramipexole—Discomfort—Pravastatin—atherosclerosis	0.00052	0.000852	CcSEcCtD
Pramipexole—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000518	0.00085	CcSEcCtD
Pramipexole—Decreased appetite—Lovastatin—atherosclerosis	0.000518	0.000849	CcSEcCtD
Pramipexole—Dyspepsia—Ezetimibe—atherosclerosis	0.000515	0.000844	CcSEcCtD
Pramipexole—Fatigue—Lovastatin—atherosclerosis	0.000514	0.000842	CcSEcCtD
Pramipexole—Oedema—Niacin—atherosclerosis	0.000512	0.000839	CcSEcCtD
Pramipexole—Pain—Lovastatin—atherosclerosis	0.00051	0.000836	CcSEcCtD
Pramipexole—Constipation—Lovastatin—atherosclerosis	0.00051	0.000836	CcSEcCtD
Pramipexole—Confusional state—Pravastatin—atherosclerosis	0.000509	0.000833	CcSEcCtD
Pramipexole—Decreased appetite—Ezetimibe—atherosclerosis	0.000508	0.000833	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000508	0.000833	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000505	0.000827	CcSEcCtD
Pramipexole—Asthenia—Rosuvastatin—atherosclerosis	0.000505	0.000827	CcSEcCtD
Pramipexole—Insomnia—Simvastatin—atherosclerosis	0.000505	0.000827	CcSEcCtD
Pramipexole—Oedema—Pravastatin—atherosclerosis	0.000504	0.000826	CcSEcCtD
Pramipexole—Fatigue—Ezetimibe—atherosclerosis	0.000504	0.000826	CcSEcCtD
Pramipexole—Shock—Niacin—atherosclerosis	0.000504	0.000826	CcSEcCtD
Pramipexole—Infection—Pravastatin—atherosclerosis	0.000501	0.000821	CcSEcCtD
Pramipexole—Paraesthesia—Simvastatin—atherosclerosis	0.000501	0.000821	CcSEcCtD
Pramipexole—Pain—Ezetimibe—atherosclerosis	0.0005	0.00082	CcSEcCtD
Pramipexole—Constipation—Ezetimibe—atherosclerosis	0.0005	0.00082	CcSEcCtD
Pramipexole—Tachycardia—Niacin—atherosclerosis	0.0005	0.000819	CcSEcCtD
Pramipexole—Pruritus—Rosuvastatin—atherosclerosis	0.000498	0.000816	CcSEcCtD
Pramipexole—Skin disorder—Niacin—atherosclerosis	0.000498	0.000815	CcSEcCtD
Pramipexole—Dyspnoea—Simvastatin—atherosclerosis	0.000497	0.000815	CcSEcCtD
Pramipexole—Hyperhidrosis—Niacin—atherosclerosis	0.000495	0.000811	CcSEcCtD
Pramipexole—Thrombocytopenia—Pravastatin—atherosclerosis	0.000494	0.000809	CcSEcCtD
Pramipexole—Feeling abnormal—Lovastatin—atherosclerosis	0.000491	0.000805	CcSEcCtD
Pramipexole—Dyspepsia—Simvastatin—atherosclerosis	0.000491	0.000805	CcSEcCtD
Pramipexole—Anorexia—Niacin—atherosclerosis	0.000488	0.0008	CcSEcCtD
Pramipexole—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000488	0.000799	CcSEcCtD
Pramipexole—Hyperhidrosis—Pravastatin—atherosclerosis	0.000488	0.000799	CcSEcCtD
Pramipexole—Decreased appetite—Simvastatin—atherosclerosis	0.000485	0.000795	CcSEcCtD
Pramipexole—Feeling abnormal—Ezetimibe—atherosclerosis	0.000482	0.00079	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000482	0.000789	CcSEcCtD
Pramipexole—Diarrhoea—Rosuvastatin—atherosclerosis	0.000481	0.000789	CcSEcCtD
Pramipexole—Fatigue—Simvastatin—atherosclerosis	0.000481	0.000788	CcSEcCtD
Pramipexole—Anorexia—Pravastatin—atherosclerosis	0.000481	0.000788	CcSEcCtD
Pramipexole—Hypotension—Niacin—atherosclerosis	0.000479	0.000784	CcSEcCtD
Pramipexole—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000478	0.000784	CcSEcCtD
Pramipexole—Pain—Simvastatin—atherosclerosis	0.000477	0.000782	CcSEcCtD
Pramipexole—Constipation—Simvastatin—atherosclerosis	0.000477	0.000782	CcSEcCtD
Pramipexole—Urticaria—Lovastatin—atherosclerosis	0.000474	0.000776	CcSEcCtD
Pramipexole—Abdominal pain—Lovastatin—atherosclerosis	0.000471	0.000772	CcSEcCtD
Pramipexole—Body temperature increased—Lovastatin—atherosclerosis	0.000471	0.000772	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000467	0.000765	CcSEcCtD
Pramipexole—Dizziness—Rosuvastatin—atherosclerosis	0.000465	0.000763	CcSEcCtD
Pramipexole—Urticaria—Ezetimibe—atherosclerosis	0.000465	0.000761	CcSEcCtD
Pramipexole—Insomnia—Niacin—atherosclerosis	0.000463	0.000759	CcSEcCtD
Pramipexole—Abdominal pain—Ezetimibe—atherosclerosis	0.000462	0.000758	CcSEcCtD
Pramipexole—Body temperature increased—Ezetimibe—atherosclerosis	0.000462	0.000758	CcSEcCtD
Pramipexole—HTR2A—liver—atherosclerosis	0.00046	0.00791	CbGeAlD
Pramipexole—Paraesthesia—Niacin—atherosclerosis	0.00046	0.000754	CcSEcCtD
Pramipexole—Feeling abnormal—Simvastatin—atherosclerosis	0.00046	0.000753	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000459	0.000753	CcSEcCtD
Pramipexole—Dyspnoea—Niacin—atherosclerosis	0.000457	0.000748	CcSEcCtD
Pramipexole—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000456	0.000747	CcSEcCtD
Pramipexole—Insomnia—Pravastatin—atherosclerosis	0.000456	0.000747	CcSEcCtD
Pramipexole—Somnolence—Niacin—atherosclerosis	0.000455	0.000746	CcSEcCtD
Pramipexole—Paraesthesia—Pravastatin—atherosclerosis	0.000453	0.000742	CcSEcCtD
Pramipexole—Dyspepsia—Niacin—atherosclerosis	0.000451	0.000739	CcSEcCtD
Pramipexole—Dyspnoea—Pravastatin—atherosclerosis	0.00045	0.000737	CcSEcCtD
Pramipexole—Decreased appetite—Niacin—atherosclerosis	0.000445	0.00073	CcSEcCtD
Pramipexole—Dyspepsia—Pravastatin—atherosclerosis	0.000444	0.000727	CcSEcCtD
Pramipexole—Rash—Rosuvastatin—atherosclerosis	0.000444	0.000727	CcSEcCtD
Pramipexole—Dermatitis—Rosuvastatin—atherosclerosis	0.000443	0.000726	CcSEcCtD
Pramipexole—Urticaria—Simvastatin—atherosclerosis	0.000443	0.000726	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Niacin—atherosclerosis	0.000442	0.000725	CcSEcCtD
Pramipexole—Body temperature increased—Simvastatin—atherosclerosis	0.000441	0.000723	CcSEcCtD
Pramipexole—Abdominal pain—Simvastatin—atherosclerosis	0.000441	0.000723	CcSEcCtD
Pramipexole—Headache—Rosuvastatin—atherosclerosis	0.000441	0.000722	CcSEcCtD
Pramipexole—Hypersensitivity—Lovastatin—atherosclerosis	0.000439	0.00072	CcSEcCtD
Pramipexole—Decreased appetite—Pravastatin—atherosclerosis	0.000438	0.000718	CcSEcCtD
Pramipexole—Pain—Niacin—atherosclerosis	0.000438	0.000718	CcSEcCtD
Pramipexole—Fatigue—Pravastatin—atherosclerosis	0.000435	0.000712	CcSEcCtD
Pramipexole—Pain—Pravastatin—atherosclerosis	0.000431	0.000707	CcSEcCtD
Pramipexole—Constipation—Pravastatin—atherosclerosis	0.000431	0.000707	CcSEcCtD
Pramipexole—Hypersensitivity—Ezetimibe—atherosclerosis	0.000431	0.000706	CcSEcCtD
Pramipexole—Asthenia—Lovastatin—atherosclerosis	0.000428	0.000701	CcSEcCtD
Pramipexole—Pruritus—Lovastatin—atherosclerosis	0.000422	0.000691	CcSEcCtD
Pramipexole—Asthenia—Ezetimibe—atherosclerosis	0.00042	0.000688	CcSEcCtD
Pramipexole—Gastrointestinal pain—Niacin—atherosclerosis	0.000419	0.000686	CcSEcCtD
Pramipexole—Nausea—Rosuvastatin—atherosclerosis	0.000418	0.000685	CcSEcCtD
Pramipexole—Feeling abnormal—Pravastatin—atherosclerosis	0.000416	0.000681	CcSEcCtD
Pramipexole—Pruritus—Ezetimibe—atherosclerosis	0.000414	0.000678	CcSEcCtD
Pramipexole—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000412	0.000676	CcSEcCtD
Pramipexole—Hypersensitivity—Simvastatin—atherosclerosis	0.000411	0.000673	CcSEcCtD
Pramipexole—Diarrhoea—Lovastatin—atherosclerosis	0.000408	0.000669	CcSEcCtD
Pramipexole—Urticaria—Niacin—atherosclerosis	0.000407	0.000667	CcSEcCtD
Pramipexole—Body temperature increased—Niacin—atherosclerosis	0.000405	0.000663	CcSEcCtD
Pramipexole—Abdominal pain—Niacin—atherosclerosis	0.000405	0.000663	CcSEcCtD
Pramipexole—Urticaria—Pravastatin—atherosclerosis	0.000401	0.000656	CcSEcCtD
Pramipexole—Asthenia—Simvastatin—atherosclerosis	0.0004	0.000656	CcSEcCtD
Pramipexole—Diarrhoea—Ezetimibe—atherosclerosis	0.0004	0.000656	CcSEcCtD
Pramipexole—Abdominal pain—Pravastatin—atherosclerosis	0.000399	0.000653	CcSEcCtD
Pramipexole—Body temperature increased—Pravastatin—atherosclerosis	0.000399	0.000653	CcSEcCtD
Pramipexole—Pruritus—Simvastatin—atherosclerosis	0.000395	0.000647	CcSEcCtD
Pramipexole—Dizziness—Lovastatin—atherosclerosis	0.000394	0.000646	CcSEcCtD
Pramipexole—Dizziness—Ezetimibe—atherosclerosis	0.000387	0.000634	CcSEcCtD
Pramipexole—Diarrhoea—Simvastatin—atherosclerosis	0.000382	0.000625	CcSEcCtD
Pramipexole—Vomiting—Lovastatin—atherosclerosis	0.000379	0.000621	CcSEcCtD
Pramipexole—Hypersensitivity—Niacin—atherosclerosis	0.000377	0.000618	CcSEcCtD
Pramipexole—Rash—Lovastatin—atherosclerosis	0.000376	0.000616	CcSEcCtD
Pramipexole—Dermatitis—Lovastatin—atherosclerosis	0.000376	0.000616	CcSEcCtD
Pramipexole—Headache—Lovastatin—atherosclerosis	0.000374	0.000612	CcSEcCtD
Pramipexole—Vomiting—Ezetimibe—atherosclerosis	0.000372	0.000609	CcSEcCtD
Pramipexole—Hypersensitivity—Pravastatin—atherosclerosis	0.000372	0.000609	CcSEcCtD
Pramipexole—Dizziness—Simvastatin—atherosclerosis	0.000369	0.000604	CcSEcCtD
Pramipexole—Rash—Ezetimibe—atherosclerosis	0.000369	0.000604	CcSEcCtD
Pramipexole—Dermatitis—Ezetimibe—atherosclerosis	0.000368	0.000604	CcSEcCtD
Pramipexole—Asthenia—Niacin—atherosclerosis	0.000368	0.000602	CcSEcCtD
Pramipexole—Headache—Ezetimibe—atherosclerosis	0.000366	0.0006	CcSEcCtD
Pramipexole—Pruritus—Niacin—atherosclerosis	0.000362	0.000594	CcSEcCtD
Pramipexole—Asthenia—Pravastatin—atherosclerosis	0.000362	0.000593	CcSEcCtD
Pramipexole—Pruritus—Pravastatin—atherosclerosis	0.000357	0.000585	CcSEcCtD
Pramipexole—Vomiting—Simvastatin—atherosclerosis	0.000355	0.000581	CcSEcCtD
Pramipexole—Nausea—Lovastatin—atherosclerosis	0.000354	0.00058	CcSEcCtD
Pramipexole—Rash—Simvastatin—atherosclerosis	0.000352	0.000576	CcSEcCtD
Pramipexole—Dermatitis—Simvastatin—atherosclerosis	0.000351	0.000576	CcSEcCtD
Pramipexole—Diarrhoea—Niacin—atherosclerosis	0.00035	0.000574	CcSEcCtD
Pramipexole—Headache—Simvastatin—atherosclerosis	0.000349	0.000573	CcSEcCtD
Pramipexole—Nausea—Ezetimibe—atherosclerosis	0.000347	0.000569	CcSEcCtD
Pramipexole—Diarrhoea—Pravastatin—atherosclerosis	0.000345	0.000565	CcSEcCtD
Pramipexole—Dizziness—Niacin—atherosclerosis	0.000339	0.000555	CcSEcCtD
Pramipexole—Dizziness—Pravastatin—atherosclerosis	0.000334	0.000546	CcSEcCtD
Pramipexole—Nausea—Simvastatin—atherosclerosis	0.000331	0.000543	CcSEcCtD
Pramipexole—Vomiting—Niacin—atherosclerosis	0.000326	0.000534	CcSEcCtD
Pramipexole—Rash—Niacin—atherosclerosis	0.000323	0.000529	CcSEcCtD
Pramipexole—Dermatitis—Niacin—atherosclerosis	0.000323	0.000529	CcSEcCtD
Pramipexole—Headache—Niacin—atherosclerosis	0.000321	0.000526	CcSEcCtD
Pramipexole—Vomiting—Pravastatin—atherosclerosis	0.000321	0.000525	CcSEcCtD
Pramipexole—Rash—Pravastatin—atherosclerosis	0.000318	0.000521	CcSEcCtD
Pramipexole—Dermatitis—Pravastatin—atherosclerosis	0.000318	0.000521	CcSEcCtD
Pramipexole—Headache—Pravastatin—atherosclerosis	0.000316	0.000518	CcSEcCtD
Pramipexole—Nausea—Niacin—atherosclerosis	0.000304	0.000499	CcSEcCtD
Pramipexole—Nausea—Pravastatin—atherosclerosis	0.0003	0.000491	CcSEcCtD
Pramipexole—DRD1—Signaling Pathways—NOS3—atherosclerosis	1.82e-05	5.48e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CCL2—atherosclerosis	1.82e-05	5.48e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CAV1—atherosclerosis	1.82e-05	5.48e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—ALB—atherosclerosis	1.81e-05	5.47e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—APOA1—atherosclerosis	1.81e-05	5.46e-05	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—TGFB1—atherosclerosis	1.81e-05	5.46e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—NOS3—atherosclerosis	1.81e-05	5.46e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—MAPK3—atherosclerosis	1.8e-05	5.44e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—LEP—atherosclerosis	1.8e-05	5.44e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—APOE—atherosclerosis	1.8e-05	5.44e-05	CbGpPWpGaD
Pramipexole—HTR1D—GPCR downstream signaling—AKT1—atherosclerosis	1.8e-05	5.42e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—MAPK3—atherosclerosis	1.79e-05	5.41e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—NOS3—atherosclerosis	1.79e-05	5.41e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—CXCL8—atherosclerosis	1.79e-05	5.4e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—IGF1—atherosclerosis	1.79e-05	5.39e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CAV1—atherosclerosis	1.79e-05	5.39e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—INS—atherosclerosis	1.78e-05	5.38e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—APOA1—atherosclerosis	1.78e-05	5.38e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—INS—atherosclerosis	1.77e-05	5.35e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PIK3CG—atherosclerosis	1.77e-05	5.34e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling by GPCR—IL6—atherosclerosis	1.77e-05	5.33e-05	CbGpPWpGaD
Pramipexole—HTR1B—GPCR downstream signaling—AKT1—atherosclerosis	1.76e-05	5.31e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CCL2—atherosclerosis	1.75e-05	5.29e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—ESR1—atherosclerosis	1.75e-05	5.28e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—MAPK3—atherosclerosis	1.75e-05	5.27e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CCL2—atherosclerosis	1.75e-05	5.26e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—NOS3—atherosclerosis	1.73e-05	5.23e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling by GPCR—IL6—atherosclerosis	1.73e-05	5.22e-05	CbGpPWpGaD
Pramipexole—DRD4—GPCR downstream signaling—AKT1—atherosclerosis	1.73e-05	5.22e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—F2—atherosclerosis	1.73e-05	5.21e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—INS—atherosclerosis	1.73e-05	5.2e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—IGF1—atherosclerosis	1.72e-05	5.2e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—ESR1—atherosclerosis	1.72e-05	5.19e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—IGF1—atherosclerosis	1.72e-05	5.18e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PDGFB—atherosclerosis	1.72e-05	5.17e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—CXCL8—atherosclerosis	1.71e-05	5.16e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PPARG—atherosclerosis	1.71e-05	5.15e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling by GPCR—IL6—atherosclerosis	1.7e-05	5.14e-05	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—PTGS2—atherosclerosis	1.7e-05	5.13e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—F2—atherosclerosis	1.7e-05	5.13e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CCL2—atherosclerosis	1.7e-05	5.12e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—SERPINE1—atherosclerosis	1.7e-05	5.12e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—MMP9—atherosclerosis	1.68e-05	5.07e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—INS—atherosclerosis	1.68e-05	5.06e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—AGT—atherosclerosis	1.67e-05	5.05e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—IGF1—atherosclerosis	1.67e-05	5.03e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Hemostasis—AKT1—atherosclerosis	1.67e-05	5.03e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—NFKB1—atherosclerosis	1.66e-05	5.02e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—PTGS2—atherosclerosis	1.65e-05	4.99e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—PIK3CG—atherosclerosis	1.65e-05	4.99e-05	CbGpPWpGaD
Pramipexole—HTR2B—GPCR downstream signaling—AKT1—atherosclerosis	1.65e-05	4.98e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—MMP9—atherosclerosis	1.65e-05	4.97e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—LEP—atherosclerosis	1.64e-05	4.95e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—APOE—atherosclerosis	1.64e-05	4.95e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—SERPINE1—atherosclerosis	1.64e-05	4.94e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—MAPK8—atherosclerosis	1.64e-05	4.93e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling by GPCR—AKT1—atherosclerosis	1.63e-05	4.92e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—SERPINE1—atherosclerosis	1.63e-05	4.91e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—NFKB1—atherosclerosis	1.63e-05	4.91e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—PIK3CG—atherosclerosis	1.63e-05	4.91e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling by GPCR—IL6—atherosclerosis	1.63e-05	4.91e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CAV1—atherosclerosis	1.63e-05	4.9e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—APOA1—atherosclerosis	1.62e-05	4.89e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—MMP9—atherosclerosis	1.62e-05	4.89e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—NOS3—atherosclerosis	1.62e-05	4.89e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—CXCL8—atherosclerosis	1.61e-05	4.87e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—NFKB1—atherosclerosis	1.6e-05	4.84e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—MAPK8—atherosclerosis	1.6e-05	4.83e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling by GPCR—AKT1—atherosclerosis	1.6e-05	4.82e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—CXCL8—atherosclerosis	1.59e-05	4.8e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—PTGS2—atherosclerosis	1.59e-05	4.78e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—SERPINE1—atherosclerosis	1.58e-05	4.78e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—MAPK3—atherosclerosis	1.58e-05	4.78e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—MAPK8—atherosclerosis	1.58e-05	4.75e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling by GPCR—AKT1—atherosclerosis	1.57e-05	4.74e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—ESR1—atherosclerosis	1.57e-05	4.72e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—INS—atherosclerosis	1.57e-05	4.72e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—NOS3—atherosclerosis	1.56e-05	4.72e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—MAPK3—atherosclerosis	1.56e-05	4.7e-05	CbGpPWpGaD
Pramipexole—DRD1—GPCR downstream signaling—AKT1—atherosclerosis	1.56e-05	4.7e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—NOS3—atherosclerosis	1.56e-05	4.69e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—MMP9—atherosclerosis	1.55e-05	4.67e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—F2—atherosclerosis	1.55e-05	4.67e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—INS—atherosclerosis	1.54e-05	4.65e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CCL2—atherosclerosis	1.54e-05	4.65e-05	CbGpPWpGaD
Pramipexole—DRD3—GPCR downstream signaling—AKT1—atherosclerosis	1.54e-05	4.64e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—ALB—atherosclerosis	1.54e-05	4.63e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling by GPCR—IL6—atherosclerosis	1.53e-05	4.63e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—NFKB1—atherosclerosis	1.53e-05	4.62e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CCL2—atherosclerosis	1.52e-05	4.57e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—IGF1—atherosclerosis	1.51e-05	4.57e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling by GPCR—IL6—atherosclerosis	1.51e-05	4.56e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—NOS3—atherosclerosis	1.51e-05	4.56e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—VEGFA—atherosclerosis	1.51e-05	4.56e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—MAPK8—atherosclerosis	1.5e-05	4.54e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling by GPCR—AKT1—atherosclerosis	1.5e-05	4.53e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—STAT3—atherosclerosis	1.5e-05	4.51e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—IGF1—atherosclerosis	1.49e-05	4.49e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PIK3CG—atherosclerosis	1.48e-05	4.47e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—VEGFA—atherosclerosis	1.48e-05	4.46e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—NOS3—atherosclerosis	1.47e-05	4.43e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—STAT3—atherosclerosis	1.46e-05	4.42e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—MMP9—atherosclerosis	1.46e-05	4.4e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—VEGFA—atherosclerosis	1.46e-05	4.39e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—NFKB1—atherosclerosis	1.44e-05	4.35e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—STAT3—atherosclerosis	1.44e-05	4.35e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—MMP9—atherosclerosis	1.44e-05	4.34e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—SERPINE1—atherosclerosis	1.44e-05	4.34e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CXCL8—atherosclerosis	1.44e-05	4.33e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—MAPK3—atherosclerosis	1.43e-05	4.31e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—NFKB1—atherosclerosis	1.42e-05	4.3e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—MAPK8—atherosclerosis	1.42e-05	4.28e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—MAPK3—atherosclerosis	1.42e-05	4.28e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling by GPCR—AKT1—atherosclerosis	1.41e-05	4.27e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—SERPINE1—atherosclerosis	1.41e-05	4.27e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—INS—atherosclerosis	1.4e-05	4.23e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—MAPK8—atherosclerosis	1.4e-05	4.22e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—MAPK3—atherosclerosis	1.4e-05	4.22e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling by GPCR—AKT1—atherosclerosis	1.4e-05	4.21e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—VEGFA—atherosclerosis	1.39e-05	4.19e-05	CbGpPWpGaD
Pramipexole—ADRA2B—GPCR downstream signaling—AKT1—atherosclerosis	1.39e-05	4.19e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CXCL8—atherosclerosis	1.39e-05	4.18e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—TGFB1—atherosclerosis	1.39e-05	4.18e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CXCL8—atherosclerosis	1.38e-05	4.16e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CCL2—atherosclerosis	1.38e-05	4.16e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—MAPK3—atherosclerosis	1.38e-05	4.15e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—STAT3—atherosclerosis	1.38e-05	4.15e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—NOS3—atherosclerosis	1.37e-05	4.14e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—IL6—atherosclerosis	1.37e-05	4.12e-05	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—IL6—atherosclerosis	1.36e-05	4.11e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—TGFB1—atherosclerosis	1.36e-05	4.09e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—IGF1—atherosclerosis	1.36e-05	4.09e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—NOS3—atherosclerosis	1.35e-05	4.07e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PTGS2—atherosclerosis	1.34e-05	4.05e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CXCL8—atherosclerosis	1.34e-05	4.05e-05	CbGpPWpGaD
Pramipexole—HTR1A—GPCR downstream signaling—AKT1—atherosclerosis	1.34e-05	4.04e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—TGFB1—atherosclerosis	1.34e-05	4.03e-05	CbGpPWpGaD
Pramipexole—HTR2C—GPCR downstream signaling—AKT1—atherosclerosis	1.33e-05	4.02e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—IL6—atherosclerosis	1.32e-05	3.98e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—MAPK3—atherosclerosis	1.31e-05	3.96e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—IL6—atherosclerosis	1.31e-05	3.96e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—VEGFA—atherosclerosis	1.31e-05	3.95e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—MMP9—atherosclerosis	1.3e-05	3.92e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—STAT3—atherosclerosis	1.3e-05	3.91e-05	CbGpPWpGaD
Pramipexole—ADRA2C—GPCR downstream signaling—AKT1—atherosclerosis	1.3e-05	3.91e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—VEGFA—atherosclerosis	1.29e-05	3.9e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—SERPINE1—atherosclerosis	1.29e-05	3.88e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—NFKB1—atherosclerosis	1.29e-05	3.88e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—STAT3—atherosclerosis	1.28e-05	3.86e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—IL6—atherosclerosis	1.28e-05	3.85e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—TGFB1—atherosclerosis	1.28e-05	3.85e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—MAPK8—atherosclerosis	1.26e-05	3.81e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—AKT1—atherosclerosis	1.26e-05	3.8e-05	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—AKT1—atherosclerosis	1.26e-05	3.79e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—MMP9—atherosclerosis	1.25e-05	3.78e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—MMP9—atherosclerosis	1.25e-05	3.76e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—NFKB1—atherosclerosis	1.24e-05	3.74e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—MAPK3—atherosclerosis	1.24e-05	3.74e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—NFKB1—atherosclerosis	1.23e-05	3.72e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—NOS3—atherosclerosis	1.23e-05	3.71e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—MAPK3—atherosclerosis	1.22e-05	3.69e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—MAPK8—atherosclerosis	1.22e-05	3.68e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CXCL8—atherosclerosis	1.22e-05	3.67e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—AKT1—atherosclerosis	1.22e-05	3.67e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—MMP9—atherosclerosis	1.21e-05	3.66e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—MAPK8—atherosclerosis	1.21e-05	3.66e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—AKT1—atherosclerosis	1.21e-05	3.65e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—TGFB1—atherosclerosis	1.2e-05	3.63e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—NFKB1—atherosclerosis	1.2e-05	3.62e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CXCL8—atherosclerosis	1.2e-05	3.61e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—TGFB1—atherosclerosis	1.19e-05	3.58e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—MAPK8—atherosclerosis	1.18e-05	3.56e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—AKT1—atherosclerosis	1.18e-05	3.55e-05	CbGpPWpGaD
Pramipexole—DRD2—GPCR downstream signaling—AKT1—atherosclerosis	1.18e-05	3.55e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—VEGFA—atherosclerosis	1.17e-05	3.52e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—IL6—atherosclerosis	1.16e-05	3.49e-05	CbGpPWpGaD
Pramipexole—HTR2A—GPCR downstream signaling—AKT1—atherosclerosis	1.16e-05	3.49e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—STAT3—atherosclerosis	1.16e-05	3.49e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—IL6—atherosclerosis	1.14e-05	3.44e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—VEGFA—atherosclerosis	1.13e-05	3.4e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—VEGFA—atherosclerosis	1.12e-05	3.38e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—STAT3—atherosclerosis	1.12e-05	3.36e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—STAT3—atherosclerosis	1.11e-05	3.35e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—MAPK3—atherosclerosis	1.1e-05	3.33e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MMP9—atherosclerosis	1.1e-05	3.32e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CXCL8—atherosclerosis	1.09e-05	3.29e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—VEGFA—atherosclerosis	1.09e-05	3.29e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—NFKB1—atherosclerosis	1.09e-05	3.29e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MMP9—atherosclerosis	1.08e-05	3.27e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—STAT3—atherosclerosis	1.08e-05	3.26e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—NFKB1—atherosclerosis	1.07e-05	3.23e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MAPK8—atherosclerosis	1.07e-05	3.23e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—TGFB1—atherosclerosis	1.07e-05	3.23e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—AKT1—atherosclerosis	1.07e-05	3.22e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—MAPK3—atherosclerosis	1.07e-05	3.21e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—MAPK3—atherosclerosis	1.06e-05	3.2e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MAPK8—atherosclerosis	1.05e-05	3.18e-05	CbGpPWpGaD
Pramipexole—ADRA2A—GPCR downstream signaling—AKT1—atherosclerosis	1.05e-05	3.18e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—AKT1—atherosclerosis	1.05e-05	3.17e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—IL6—atherosclerosis	1.04e-05	3.15e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—IL6—atherosclerosis	1.04e-05	3.13e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—TGFB1—atherosclerosis	1.03e-05	3.12e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—MAPK3—atherosclerosis	1.03e-05	3.11e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—TGFB1—atherosclerosis	1.03e-05	3.1e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—IL6—atherosclerosis	1.02e-05	3.09e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—IL6—atherosclerosis	1.01e-05	3.04e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—TGFB1—atherosclerosis	1e-05	3.02e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—VEGFA—atherosclerosis	9.89e-06	2.98e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MMP9—atherosclerosis	9.86e-06	2.97e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—STAT3—atherosclerosis	9.79e-06	2.95e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—NFKB1—atherosclerosis	9.76e-06	2.94e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—VEGFA—atherosclerosis	9.73e-06	2.94e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—STAT3—atherosclerosis	9.64e-06	2.91e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—AKT1—atherosclerosis	9.64e-06	2.91e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—IL6—atherosclerosis	9.61e-06	2.9e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MAPK8—atherosclerosis	9.59e-06	2.89e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—AKT1—atherosclerosis	9.56e-06	2.88e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—AKT1—atherosclerosis	9.44e-06	2.85e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MAPK3—atherosclerosis	9.36e-06	2.82e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—AKT1—atherosclerosis	9.29e-06	2.8e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MAPK3—atherosclerosis	9.21e-06	2.78e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—TGFB1—atherosclerosis	9.08e-06	2.74e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—IL6—atherosclerosis	9.06e-06	2.73e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—IL6—atherosclerosis	8.94e-06	2.7e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—TGFB1—atherosclerosis	8.93e-06	2.69e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—AKT1—atherosclerosis	8.86e-06	2.67e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—VEGFA—atherosclerosis	8.85e-06	2.67e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—STAT3—atherosclerosis	8.77e-06	2.64e-05	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—AKT1—atherosclerosis	8.55e-06	2.58e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MAPK3—atherosclerosis	8.38e-06	2.53e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—AKT1—atherosclerosis	8.36e-06	2.52e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—AKT1—atherosclerosis	8.32e-06	2.51e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—AKT1—atherosclerosis	8.25e-06	2.49e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—TGFB1—atherosclerosis	8.13e-06	2.45e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—IL6—atherosclerosis	8.07e-06	2.43e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—AKT1—atherosclerosis	7.97e-06	2.4e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—IL6—atherosclerosis	7.79e-06	2.35e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—IL6—atherosclerosis	7.75e-06	2.34e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—IL6—atherosclerosis	7.54e-06	2.27e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—AKT1—atherosclerosis	7.45e-06	2.25e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—AKT1—atherosclerosis	7.19e-06	2.17e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—AKT1—atherosclerosis	7.15e-06	2.16e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—AKT1—atherosclerosis	6.96e-06	2.1e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—IL6—atherosclerosis	6.84e-06	2.06e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—AKT1—atherosclerosis	6.76e-06	2.04e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—IL6—atherosclerosis	6.73e-06	2.03e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—AKT1—atherosclerosis	6.31e-06	1.9e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—AKT1—atherosclerosis	6.21e-06	1.87e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—IL6—atherosclerosis	6.12e-06	1.85e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—AKT1—atherosclerosis	5.65e-06	1.7e-05	CbGpPWpGaD
